anti bacterial agents

Summary

Summary: Substances that reduce the growth or reproduction of BACTERIA.

Top Publications

  1. ncbi Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults
    Lionel A Mandell
    McMaster University Medical School, Hamilton, Ontario, Canada
    Clin Infect Dis 44:S27-72. 2007
  2. ncbi A common mechanism of cellular death induced by bactericidal antibiotics
    Michael A Kohanski
    Center for BioDynamics and Center for Advanced Biotechnology, Boston University, Boston, MA 02215, USA
    Cell 130:797-810. 2007
  3. ncbi Antimicrobial peptides of multicellular organisms
    Michael Zasloff
    Department of Biochemistry and Biophysics, University of Pennsylvania School of Medicine, Philadelphia 19104 6059, USA
    Nature 415:389-95. 2002
  4. ncbi Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?
    Kim A Brogden
    Department of Periodontics and Dows Institute for Dental Research, College of Dentistry, The University of Iowa, Iowa City, Iowa 52242, USA
    Nat Rev Microbiol 3:238-50. 2005
  5. ncbi Outpatient antibiotic use in Europe and association with resistance: a cross-national database study
    Herman Goossens
    ESAC Management Team, Department of Microbiology, University of Antwerp, B 2610 Antwerp, Belgium
    Lancet 365:579-87. 2005
  6. ncbi Antibacterial resistance worldwide: causes, challenges and responses
    Stuart B Levy
    Center for Adaptation Genetics and Drug Resistance, Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Nat Med 10:S122-9. 2004
  7. pmc Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance
    I Chopra
    Antimicrobial Research Centre and Division of Microbiology, School of Biochemistry and Molecular Biology, University of Leeds, Leeds LS2 9JT, United Kingdom
    Microbiol Mol Biol Rev 65:232-60 ; second page, table of contents. 2001
  8. pmc Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli
    Iris Keren
    Department of Biology, Northeastern University, 134 Mugar Hall, 360 Huntington Ave, Boston, MA 02115
    J Bacteriol 186:8172-80. 2004
  9. ncbi Typhoid fever
    Christopher M Parry
    Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
    N Engl J Med 347:1770-82. 2002
  10. pmc Extended-spectrum beta-lactamases: a clinical update
    David L Paterson
    Infectious Disease Division, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Clin Microbiol Rev 18:657-86. 2005

Detail Information

Publications353 found, 100 shown here

  1. ncbi Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults
    Lionel A Mandell
    McMaster University Medical School, Hamilton, Ontario, Canada
    Clin Infect Dis 44:S27-72. 2007
  2. ncbi A common mechanism of cellular death induced by bactericidal antibiotics
    Michael A Kohanski
    Center for BioDynamics and Center for Advanced Biotechnology, Boston University, Boston, MA 02215, USA
    Cell 130:797-810. 2007
    ..g., reca...
  3. ncbi Antimicrobial peptides of multicellular organisms
    Michael Zasloff
    Department of Biochemistry and Biophysics, University of Pennsylvania School of Medicine, Philadelphia 19104 6059, USA
    Nature 415:389-95. 2002
    ..What sorts of molecules are they? How are they employed by animals in their defence? As our need for new antibiotics becomes more pressing, could we design anti-infective drugs based on the design principles these molecules teach us?..
  4. ncbi Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?
    Kim A Brogden
    Department of Periodontics and Dows Institute for Dental Research, College of Dentistry, The University of Iowa, Iowa City, Iowa 52242, USA
    Nat Rev Microbiol 3:238-50. 2005
    ..In this review the different models of antimicrobial-peptide-induced pore formation and cell killing are presented...
  5. ncbi Outpatient antibiotic use in Europe and association with resistance: a cross-national database study
    Herman Goossens
    ESAC Management Team, Department of Microbiology, University of Antwerp, B 2610 Antwerp, Belgium
    Lancet 365:579-87. 2005
    ..Our aim was to assess outpatient use of antibiotics and the association with resistance...
  6. ncbi Antibacterial resistance worldwide: causes, challenges and responses
    Stuart B Levy
    Center for Adaptation Genetics and Drug Resistance, Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Nat Med 10:S122-9. 2004
    ..Drug resistance presents an ever-increasing global public health threat that involves all major microbial pathogens and antimicrobial drugs...
  7. pmc Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance
    I Chopra
    Antimicrobial Research Centre and Division of Microbiology, School of Biochemistry and Molecular Biology, University of Leeds, Leeds LS2 9JT, United Kingdom
    Microbiol Mol Biol Rev 65:232-60 ; second page, table of contents. 2001
    ..Changing the use of tetracyclines in human and animal health as well as in food production is needed if we are to continue to use this class of broad-spectrum antimicrobials through the present century...
  8. pmc Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli
    Iris Keren
    Department of Biology, Northeastern University, 134 Mugar Hall, 360 Huntington Ave, Boston, MA 02115
    J Bacteriol 186:8172-80. 2004
    ..The function of these specialized dormant cells is to ensure the survival of the population in the presence of lethal factors...
  9. ncbi Typhoid fever
    Christopher M Parry
    Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
    N Engl J Med 347:1770-82. 2002
  10. pmc Extended-spectrum beta-lactamases: a clinical update
    David L Paterson
    Infectious Disease Division, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Clin Microbiol Rev 18:657-86. 2005
    ..ESBLs represent an impressive example of the ability of gram-negative bacteria to develop new antibiotic resistance mechanisms in the face of the introduction of new antimicrobial agents...
  11. ncbi Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship
    Timothy H Dellit
    Harborview Medical Center and the University of Washington, Seattle, USA
    Clin Infect Dis 44:159-77. 2007
  12. pmc Peptide antimicrobial agents
    Håvard Jenssen
    Centre for Microbial Diseases and Immunity Research, University of British Columbia, Lower Mall Research Station, 232 2259 Lower Mall, Vancouver, British Columbia V6T 1Z4, Canada
    Clin Microbiol Rev 19:491-511. 2006
    ..Knowledge regarding the relationship between peptide structure and function as well as their mechanism of action is being applied in the design of antimicrobial peptide variants as potential novel therapeutic agents...
  13. pmc Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat
    P A Bradford
    Wyeth Ayerst Research, Pearl River, New York 10965, USA
    Clin Microbiol Rev 14:933-51, table of contents. 2001
    ..They have also been found in other Enterobacteriaceae strains and Pseudomonas aeruginosa. Strains expressing these beta-lactamases will present a host of therapeutic challenges as we head into the 21st century...
  14. ncbi Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillanc
    D J Diekema
    Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52242, USA
    Clin Infect Dis 32:S114-32. 2001
    ..Given the increasing multidrug resistance among staphylococci and the possible emergence of vancomycin-resistant strains, global strategies are needed to control emergence and spread of multiply resistant staphylococci...
  15. ncbi Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity
    I Wiedemann
    , D-53105 Bonn, Germany
    J Biol Chem 276:1772-9. 2001
    ..The combination of two killing mechanisms in one molecule potentiates antibiotic activity and results in nanomolar MIC values, a strategy that may well be worth considering for the construction of novel antibiotics...
  16. pmc Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity
    Jacques Pepin
    Department of Microbiology and Infectious Diseases, University of Sherbrooke, Sherbrooke, Que
    CMAJ 171:466-72. 2004
    ..difficile-associated diarrhea (CDAD) in our institution. We describe cases of CDAD at our institution over a 13-year period and investigate changes in illness severity...
  17. ncbi Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation
    Eliana Drenkard
    Department of Genetics, Harvard Medical School, Massahusetts General Hospital, Boston, MA 02114, USA
    Nature 416:740-3. 2002
    ..Compounds that affect PvrR function could have an important role in the treatment of CF infections...
  18. ncbi Aminoglycoside antibiotics induce bacterial biofilm formation
    Lucas R Hoffman
    Department of Pediatrics, University of Washington, Seattle, Washington 98195, USA
    Nature 436:1171-5. 2005
    ..Our results demonstrate that biofilm formation can be a specific, defensive reaction to the presence of antibiotics, and indicate that the molecular basis of this response includes alterations in the level of c-di-GMP...
  19. ncbi The worldwide emergence of plasmid-mediated quinolone resistance
    Ari Robicsek
    Massachusetts General Hospital, Boston, MA 02114 2696, USA
    Lancet Infect Dis 6:629-40. 2006
    ....
  20. ncbi Practice guidelines for the diagnosis and management of skin and soft-tissue infections
    Dennis L Stevens
    Infectious Diseases Section, Veterans Affairs Medical Center, Boise, Idaho 83702, USA
    Clin Infect Dis 41:1373-406. 2005
  21. ncbi Recognition of cognate transfer RNA by the 30S ribosomal subunit
    J M Ogle
    MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 2QH, UK
    Science 292:897-902. 2001
    ..The third, or "wobble," position of the codon is free to accommodate certain noncanonical base pairs. By partially inducing these structural changes, paromomycin facilitates binding of near-cognate tRNAs...
  22. ncbi Mode of action of membrane active antimicrobial peptides
    Yechiel Shai
    Department of Biological Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel
    Biopolymers 66:236-48. 2002
    ..Further, although many studies support that bacterial membrane damage is a lethal event for bacteria, other studies point to a multihit mechanism in which the peptide binds to several targets in the cytoplasmic region of the bacteria...
  23. pmc Analysis of a complete library of putative drug transporter genes in Escherichia coli
    K Nishino
    Department of Cell Membrane Biology, Institute of Scientific and Industrial Research, Osaka University, Ibaraki, Osaka 567-0047, Japan
    J Bacteriol 183:5803-12. 2001
    ..Of these 20 ORFs, cusA, yegMNO, ydgFE, yceE, yceL, yidY, and ybjYZ are novel drug resistance genes. The fsr, bcr, yjiO, ydhE, acrD, and yhiUV genes gave broader resistance spectra than previously reported...
  24. pmc Lipopolysaccharide endotoxins
    Christian R H Raetz
    Department of Biochemistry, Duke University Medical Center, Durham, North Carolina 27710, USA
    Annu Rev Biochem 71:635-700. 2002
    ..The expanding knowledge of TLR4 specificity and its downstream signaling pathways should provide new opportunities for blocking inflammation associated with infection...
  25. ncbi Determination of minimum inhibitory concentrations
    J M Andrews
    Department of Microbiology, City Hospital NHS Trust, Birmingham B18 7QH, UK
    J Antimicrob Chemother 48:5-16. 2001
    ..Tables giving expected MIC ranges for control NCTC and ATCC strains are also supplied...
  26. pmc The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms
    H Ceri
    Biofilm Research Group, University of Calgary, Calgary, Alberta, Canada T2N 1N4
    J Clin Microbiol 37:1771-6. 1999
    ..The CBD offers a new technology for the rational selection of antibiotics effective against microbial biofilms and for the screening of new effective antibiotic compounds...
  27. ncbi Non-inherited antibiotic resistance
    Bruce R Levin
    Department of Biology, Emory University, Atlanta, Georgia 30307, USA
    Nat Rev Microbiol 4:556-62. 2006
    ....
  28. pmc Transposon vectors containing non-antibiotic resistance selection markers for cloning and stable chromosomal insertion of foreign genes in gram-negative bacteria
    M Herrero
    GBF National Research Centre for Biotechnology, Braunschweig, Federal Republic of Germany
    J Bacteriol 172:6557-67. 1990
    ..g., in open systems and natural environments), and that do not carry antibiotic resistance markers characteristic of most available cloning vectors (as is currently required of live bacterial vaccines)...
  29. ncbi Persister cells and tolerance to antimicrobials
    Iris Keren
    Department of Biology, Northeastern University, Boston, MA 02115, USA
    FEMS Microbiol Lett 230:13-8. 2004
    ..This suggests that persisters are not at a particular stage in the cell cycle, neither are they defective cells nor cells created in response to antibiotics. Our data indicate that persisters are specialized survivor cells...
  30. ncbi The world of subinhibitory antibiotic concentrations
    Julian Davies
    Department of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia V6T 01Z3, Canada
    Curr Opin Microbiol 9:445-53. 2006
    ..These analyses should be of value in providing information on antibiotic side-effects, in bioactive natural product discovery and antibiotic mode-of-action studies...
  31. ncbi Infective endocarditis
    Philippe Moreillon
    Institute of Fundamental Microbiology, Centre Hospitalier Universitaire, University of Lausanne, Switzerland
    Lancet 363:139-49. 2004
    ..New ideas for antimicrobial agents are being developed. These novel insights should help redefine preventive and therapeutic strategies against infective endocarditis...
  32. ncbi Efflux-mediated antimicrobial resistance
    Keith Poole
    Department of Microbiology and Immunology, Queen s University, Kingston, ON, Canada
    J Antimicrob Chemother 56:20-51. 2005
    ....
  33. ncbi SOS response induction by beta-lactams and bacterial defense against antibiotic lethality
    Christine Miller
    Department of Genetics, Stanford University, Stanford, CA 94305, USA
    Science 305:1629-31. 2004
    ....
  34. ncbi Bacterial persistence as a phenotypic switch
    Nathalie Q Balaban
    Laboratory of Living Matter and Center for Studies in Physics and Biology, Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    Science 305:1622-5. 2004
    ..Inherent heterogeneity of bacterial populations may be important in adaptation to fluctuating environments and in the persistence of bacterial infections...
  35. pmc Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community
    Keiko Okuma
    Department of Bacteriology, Juntendo University, Tokyo, Japan
    J Clin Microbiol 40:4289-94. 2002
    ..They multiplied much faster than health-care-associated MRSA and were resistant to fewer non-beta-lactam antibiotics. They seem to have been derived from more diverse S. aureus populations than health-care-associated MRSA strains...
  36. pmc Persisters: a distinct physiological state of E. coli
    Devang Shah
    Department of Biology, Northeastern University, 134 Mugar Hall, 360 Huntington Ave, Boston, MA 02115, USA
    BMC Microbiol 6:53. 2006
    ..Recent progress in understanding persisters is encouraging, but the main obstacle in understanding their nature was our inability to isolate these elusive cells from a wild-type population since their discovery in 1944...
  37. pmc Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report
    P Malfertheiner
    Otto von Guericke Universitat Magdeburg, Medizinische Fakultat, Zentrum fur Innere Medizin, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Leipziger Strasse 44, D 39120 Magdeburg, Germany
    Gut 56:772-81. 2007
    ..Guidelines on the management of Helicobacter pylori, which cover indications for management and treatment strategies, were produced in 2000...
  38. ncbi Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides
    A Peschel
    Mikrobielle Genetik, Universitat Tubingen, Waldhäuser Strasse 70 8, 72076 Tubingen, Germany
    J Biol Chem 274:8405-10. 1999
    ..We propose a role of the D-alanine-esterified teichoic acids which occur in many pathogenic bacteria in the protection against human and animal defense systems...
  39. ncbi Sampling the antibiotic resistome
    Vanessa M D'Costa
    Antimicrobial Research Centre, Department of Biochemistry and Biomedical Sciences, McMaster University, Ontario, Canada, L8N 3Z5
    Science 311:374-7. 2006
    ..They are a reservoir of resistance determinants that can be mobilized into the microbial community. Study of this reservoir could provide an early warning system for future clinically relevant antibiotic resistance mechanisms...
  40. ncbi Trends in antimicrobial drug development: implications for the future
    Brad Spellberg
    Research and Education Institute and Department of Medicine, Harbor University of California, Los Angeles Medical Center, Torrance, California 90502, USA
    Clin Infect Dis 38:1279-86. 2004
    ..Despite the critical need for new antimicrobial agents, the development of these agents is declining. Solutions encouraging and facilitating the development of new antimicrobial agents are needed...
  41. ncbi Isolation and characterization of human beta -defensin-3, a novel human inducible peptide antibiotic
    J Harder
    Clinical Research Unit, Department of Dermatology, University Hospital Kiel, Schittenhelmstrasse 7, 24105 Kiel, Germany
    J Biol Chem 276:5707-13. 2001
    ..hBD-3 therefore might be important in the innate epithelial defense of infections by various microorganisms seen in skin and lung, such as cystic fibrosis...
  42. ncbi Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
    Jeffrey D Rothstein
    Department of Neurology, Johns Hopkins University, Baltimore, Maryland 21287, USA
    Nature 433:73-7. 2005
    ..Thus these studies provide a class of potential neurotherapeutics that act to modulate the expression of glutamate neurotransmitter transporters via gene activation...
  43. ncbi Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections
    Matthew E Falagas
    Alfa Institute of Biomedical Sciences, Athens, Greece
    Clin Infect Dis 40:1333-41. 2005
    ....
  44. ncbi Heavy use of prophylactic antibiotics in aquaculture: a growing problem for human and animal health and for the environment
    Felipe C Cabello
    Department of Microbiology and Immunology, New York Medical College, Valhalla, NY 10595, USA
    Environ Microbiol 8:1137-44. 2006
    ....
  45. pmc Antibiotics as signalling molecules
    Grace Yim
    Department of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, Canada
    Philos Trans R Soc Lond B Biol Sci 362:1195-200. 2007
    ..Thus, microbial metabolites constitute a large collection of cell-signalling molecules that regulate gene expression in microbial populations and possibly the interactions of these populations with the surrounding organisms...
  46. ncbi The antibiotic resistome: the nexus of chemical and genetic diversity
    Gerard D Wright
    Antimicrobial Research Centre, Department of Biochemistry and Biomedical Sciences, DeGroote School of Medicine, McMaster University, 1200 Main Street West Hamilton, Ontario, L8N 3Z5, Canada
    Nat Rev Microbiol 5:175-86. 2007
    ..Why is resistance inevitable and where does it come from? Understanding the molecular diversity that underlies resistance will inform our use of these drugs and guide efforts to develop new efficacious antibiotics...
  47. pmc Mistranslation of membrane proteins and two-component system activation trigger antibiotic-mediated cell death
    Michael A Kohanski
    Department of Biomedical Engineering, Center for BioDynamics, and Center for Advanced Biotechnology, Boston University, Boston, MA 02215, USA
    Cell 135:679-90. 2008
    ....
  48. ncbi Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections
    G A Pankey
    Section of Infectious Diseases, Ochsner Clinic Foundation, New Orleans, Louisiana 70121 2483, USA
    Clin Infect Dis 38:864-70. 2004
    ..The ultimate guide to treatment of any infection must be clinical outcome...
  49. ncbi The patient's role in the spread and control of bacterial resistance to antibiotics
    Peter Davey
    MEMO, University of Dundee, Dundee, UK, Tayside Center for General Practice, Dundee, UK
    Clin Microbiol Infect 8:43-68. 2002
    ..This, in turn, may help to control the development and spread of resistance to antibiotics...
  50. pmc Multidrug efflux pumps of gram-negative bacteria
    H Nikaido
    Department of Molecular and Cell Biology, University of California, Berkeley 94720 3206, USA
    J Bacteriol 178:5853-9. 1996
  51. pmc Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus
    Jared A Silverman
    Cubist Pharmaceuticals, Inc, Lexington, Massachusetts 02421, USA
    Antimicrob Agents Chemother 47:2538-44. 2003
    ..This study demonstrates a clear correlation between dissipation of membrane potential and the bactericidal activity of daptomycin. A multistep model for daptomycin's mechanism of action is proposed...
  52. ncbi Molecular mechanisms of antibacterial multidrug resistance
    Michael N Alekshun
    Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    Cell 128:1037-50. 2007
    ..Once established, multidrug-resistant organisms persist and spread worldwide, causing clinical failures in the treatment of infections and public health crises...
  53. pmc beta-lactam antibiotics induce the SOS response and horizontal transfer of virulence factors in Staphylococcus aureus
    Elisa Maiques
    Departamento de Quimica, Bioquimica y Biologia Molecular, Universidad Cardenal Herrera CEU, 46113 Moncada, Valencia, Spain
    J Bacteriol 188:2726-9. 2006
    ....
  54. ncbi Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?
    David M Livermore
    Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, Colindale, London, United Kingdom
    Clin Infect Dis 34:634-40. 2002
    ..A few isolates of P. aeruginosa are resistant to all reliable antibiotics, and this problem seems likely to grow with the emergence of integrins that carry gene cassettes encoding both carbapenemases and amikacin acetyltransferases...
  55. ncbi Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004
    Lauri A Hicks
    Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Infect Dis 196:1346-54. 2007
    ..The benefits may be offset by increases in disease due to serotypes not included in the vaccine (hereafter, "nonvaccine serotypes"). We evaluated the effect of PCV7 on incidence of disease due to nonvaccine serotypes...
  56. ncbi Antibiotics and antibiotic resistance in water environments
    Fernando Baquero
    Department of Microbiology, Ramon y Cajal University Hospital, CIBER ESP, Spain
    Curr Opin Biotechnol 19:260-5. 2008
    ..A policy for preventing mixing human-originated and animal-originated bacteria with environmental organisms seems advisable...
  57. ncbi Two-component signal transduction
    A M Stock
    Center for Advanced Biotechnology and Medicine and Howard Hughes Medical Institute, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, USA
    Annu Rev Biochem 69:183-215. 2000
    ..Thus detailed analyses of a relatively small number of representative proteins provide a foundation for understanding this large family of signaling proteins...
  58. ncbi Methicillin-resistant S. aureus infections among patients in the emergency department
    Gregory J Moran
    Department of Emergency Medicine, Olive View UCLA Medical Center, Sylmar, Calif 91342, USA
    N Engl J Med 355:666-74. 2006
    ..Methicillin-resistant Staphylococcus aureus (MRSA) is increasingly recognized in infections among persons in the community without established risk factors for MRSA...
  59. pmc Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines
    W S Lim
    Respiratory Infection Research Group, Respiratory Medicine, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK
    Thorax 56:296-301. 2001
    ..Atypical pathogens are more common in younger patients. They should also be covered in all patients with severe pneumonia and younger patients with non-severe infection...
  60. pmc Integrons and gene cassettes in the enterobacteriaceae
    P A White
    Virology Division, Department of Microbiology, SEALS, Prince of Wales Hospital, Randwick, Sydney NSW 2031, Australia
    Antimicrob Agents Chemother 45:2658-61. 2001
    ..PCR sequencing analysis of the cassette arrays revealed a predominance of cassettes that confer resistance to the aminoglycosides and trimethoprim...
  61. pmc AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants
    H Okusu
    Department of Molecular and Cell Biology, University of California, Berkeley 94720, USA
    J Bacteriol 178:306-8. 1996
    ..This experiment identified the AcrAB system as the major pump responsible for making the Mar mutants resistant to many agents, including tetracycline, chloramphenicol, ampicillin, nalidixic acid, and rifampin...
  62. ncbi SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus
    Carlene A Muto
    Division of Hospital Epidemiology and Infection Control, UPMC P, Pittsburgh, Pennsylvania 15213, USA
    Infect Control Hosp Epidemiol 24:362-86. 2003
    ..After 2 more years without improvement, a SHEA task force was appointed to draft this evidence-based guideline on preventing nosocomial transmission of such pathogens, focusing on the two considered most out of control: MRSA and VRE...
  63. ncbi Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin
    K Hiramatsu
    Department of Bacteriology, Juntendo University, Tokyo, Japan
    Lancet 350:1670-3. 1997
    ..Two important questions need to be answered: (1) what is the prevalence of VRSA, and (2) by what mechanism does vancomycin resistance occur...
  64. pmc A European study on the relationship between antimicrobial use and antimicrobial resistance
    Stef L A M Bronzwaer
    National Institute of Public Health and the Environment, Department of Infectious Disease Epidemiology, Postbak 75, PO Box 1, Antonie van Leeuwenhoeklaan 9, 3720 BA Bilthoven, The Netherlands
    Emerg Infect Dis 8:278-82. 2002
    ..Our results show that in Europe antimicrobial resistance of S. pneumoniae to penicillin is correlated with use of beta-lactam antibiotics and macrolides...
  65. pmc Antimicrobial use and antimicrobial resistance: a population perspective
    Marc Lipsitch
    Department of Epidemiology, Harvard School of Public Health, Boston, Massachussetts 02115, USA
    Emerg Infect Dis 8:347-54. 2002
    ..These mechanisms can operate even when treatment has a modest, or even negative, effect on an individual host's colonization with resistant organisms...
  66. pmc Rapid dissemination and diversity of CTX-M extended-spectrum beta-lactamase genes in commensal Escherichia coli isolates from healthy children from low-resource settings in Latin America
    Lucia Pallecchi
    Dipartimento di Biologia Molecolare, Sezione di Microbiologia, Universita di Siena, Policlinico Santa Maria alle Scotte, Siena, Italy
    Antimicrob Agents Chemother 51:2720-5. 2007
    ..Three CTX-M-15-encoding conjugative plasmids from Peruvian isolates carried the new fluoroquinolone resistance gene aac(6')-Ib-cr. To our best knowledge, this is the first report of the detection of aac(6')-Ib-cr in Latin America...
  67. ncbi The biological cost of antibiotic resistance
    D I Andersson
    Department of Bacteriology Swedish Institute for Infectious Disease Control S 17182, Solna, Sweden
    Curr Opin Microbiol 2:489-93. 1999
    ..The data available from recent laboratory studies suggest that most, but not all, resistance-determining mutations and accessory elements engender some fitness cost, but those costs are likely to be ameliorated by subsequent evolution...
  68. pmc The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions
    M Lipsitch
    Department of Biology, Emory University, 1510 Clifton Road, Atlanta, GA 30322, USA
    Proc Natl Acad Sci U S A 97:1938-43. 2000
    ..The predictions of the model are compared with those of other models and published data. The implications for resistance control and study design are discussed, along with the limitations and assumptions of the model...
  69. ncbi Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis
    Veronika Brundula
    Department of Clinical Neurosciences, University of Calgary, Canada
    Brain 125:1297-308. 2002
    ..These results indicate that minocycline may constitute a safe and inexpensive therapy for multiple sclerosis...
  70. ncbi Effect of pneumonia case management on mortality in neonates, infants, and preschool children: a meta-analysis of community-based trials
    Sunil Sazawal
    Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA
    Lancet Infect Dis 3:547-56. 2003
    ..Community-based interventions to identify and treat pneumonia have a substantial effect on neonatal, infant, and child mortality and should be incorporated into primary health care...
  71. pmc Transcriptional modulation of bacterial gene expression by subinhibitory concentrations of antibiotics
    Ee Been Goh
    Department of Microbiology and Immunology, University of British Columbia, 300 6174 University Boulevard, Vancouver, BC, Canada V6T 1Z3
    Proc Natl Acad Sci U S A 99:17025-30. 2002
    ....
  72. pmc Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin
    George Sakoulas
    Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115, USA
    Antimicrob Agents Chemother 46:1492-502. 2002
    ..These findings imply that compromised agr function is advantageous to clinical isolates of S. aureus toward the development of vancomycin heteroresistance, perhaps through the development of vancomycin tolerance...
  73. ncbi Otitis media
    Maroeska M Rovers
    Julius Centre for Health Sciences and Primary Care, University Medical Centre, PO Box 85060, 3508 AB, Utrecht, Netherlands
    Lancet 363:465-73. 2004
    ..The ideal intervention for OM, however, does not yet exist, and an urgent need remains to explore new and creative options based on modern insights into the pathophysiology of OM...
  74. pmc Detection of erythromycin-resistant determinants by PCR
    J Sutcliffe
    Department of Infectious Diseases, Pfizer, Inc, Groton, Connecticut 06340, USA
    Antimicrob Agents Chemother 40:2562-6. 1996
    ..Further, this methodology could be useful in surveillance studies of erythromycin-resistant determinants...
  75. ncbi A sensitive and quick microplate method to determine the minimal inhibitory concentration of plant extracts for bacteria
    J N Eloff
    Department of Pharmacology, University of Pretoria, South Africa
    Planta Med 64:711-3. 1998
    ..MIC values determined for sulfisoxazole, norfloxacin, gentamicin, and nitrofuratoin were similar to values indicated in the literature but values obtained with trimethroprim and ampicillin were higher with some bacteria...
  76. pmc Rapid diagnostic tests compared with malaria microscopy for guiding outpatient treatment of febrile illness in Tanzania: randomised trial
    Hugh Reyburn
    Department of Infectious and Tropical Disease, London School of Hygiene and Tropical Medicine, London WCIE 7HT
    BMJ 334:403. 2007
    ..To compare rapid diagnostic tests (RDTs) for malaria with routine microscopy in guiding treatment decisions for febrile patients...
  77. ncbi Resistance in gram-negative bacteria: enterobacteriaceae
    David L Paterson
    Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Am J Med 119:S20-8; discussion S62-70. 2006
    ..Better antibiotic stewardship and infection control are needed to prevent further spread of ESBLs and other forms of resistance in Enterobacteriaceae throughout the world...
  78. ncbi Predicting the clinical course of suspected acute viral upper respiratory tract infection in children
    Christopher C Butler
    Department of General Practice, Cardiff University, Llanedeyrn Health Centre, Cardiff CF23 9PN, UK
    Fam Pract 22:92-5. 2005
    ....
  79. ncbi Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey
    Stan Deresinski
    Division of Infectious Disease and Geographic Medicine, Department of Medicine, Stanford University, Stanford, CA, USA
    Clin Infect Dis 40:562-73. 2005
    ..This has led to an important change in the choice of antibiotics in the management of community-acquired infections and has also led to the development of novel antimicrobials...
  80. ncbi A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use
    Carlene A Muto
    Division of Hospital Epidemiology and Infection Control, University of Pittsburgh Medical Center, Presbyterian Campus, Pittsburgh, Pennsylvania 15213, USA
    Infect Control Hosp Epidemiol 26:273-80. 2005
    ..difficile infections; of these, 26 resulted in colectomy and 18 resulted in death. We conducted an investigation of a large C. difficile outbreak in our hospital to identify risk factors and characterize the outbreak...
  81. ncbi Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group
    W Zimmerli
    Department of Internal Medicine, University Hospitals, Basel, Switzerland
    JAMA 279:1537-41. 1998
    ..Rifampin-containing regimens are able to cure staphylococcal implant-related infections based on in vitro and in vivo observations. However, this evidence has not been proven by a controlled clinical trial...
  82. ncbi The new beta-lactamases
    George A Jacoby
    Department of Infectious Diseases, Lahey Clinic, Burlington, Mass 01805, USA
    N Engl J Med 352:380-91. 2005
  83. pmc Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network
    L McGee
    MRC SAIMR Wits Pneumococcal Diseases Research Unit, Johannesburg, South Africa
    J Clin Microbiol 39:2565-71. 2001
    ..This network can serve as a prototype for the collaboration of scientists in identifying clones of important human pathogens and as a model for the development of other networks...
  84. ncbi Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005
    Matthew R Moore
    Respiratory Diseases Branch, Centers for Disease Control and Prevention, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA
    J Infect Dis 197:1016-27. 2008
    ..To understand this increase, we characterized serotype 19A isolates recovered during 2005...
  85. pmc Characterization of multiple-antimicrobial-resistant Escherichia coli isolates from diseased chickens and swine in China
    Hanchun Yang
    China Agricultural University, Beijing, China
    J Clin Microbiol 42:3483-9. 2004
    ....
  86. pmc Oxygen limitation contributes to antibiotic tolerance of Pseudomonas aeruginosa in biofilms
    Giorgia Borriello
    Center for Biofilm Engineering and Department of Chemical Engineering, Montana State University Bozeman, Bozeman, MT 59717 3980, USA
    Antimicrob Agents Chemother 48:2659-64. 2004
    ..Local oxygen limitation and the presence of nitrate may contribute to the reduced susceptibilities of P. aeruginosa biofilms causing infections in vivo...
  87. ncbi Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia
    Ki Tae Kwon
    Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon dong, Seoul 135 710, Korea
    J Antimicrob Chemother 59:525-30. 2007
    ..To investigate the impact of imipenem resistance on the mortality rate among patients with Acinetobacter bacteraemia...
  88. ncbi Synergism between natural products and antibiotics against infectious diseases
    Shanmugam Hemaiswarya
    Department of Biotechnology, Indian Institute of Technology Madras, Chennai 600 036, India
    Phytomedicine 15:639-52. 2008
    ..The mode of action of combination differs significantly than that of the same drugs acting individually; hence isolating a single component may lose its importance thereby simplifying the task of pharma industries...
  89. pmc Unexpected occurrence of plasmid-mediated quinolone resistance determinants in environmental Aeromonas spp
    Vincent Cattoir
    Institut Nationale de la Santé et de la Recherche Médicale Unité 914, Le Kremlin Bicetre, France
    Emerg Infect Dis 14:231-7. 2008
    ..This identification of plasmid-mediated qnr genes outside Enterobacteriaceae underlines a possible diffusion of those resistance determinants within gram-negative rods...
  90. ncbi Bistability in bacteria
    David Dubnau
    Public Health Research Institute, 225 Warren Street, Newark, NJ 07103, USA
    Mol Microbiol 61:564-72. 2006
    ..A review describing additional examples of bistability in bacteria has been published recently...
  91. pmc Carbapenemases: the versatile beta-lactamases
    Anne Marie Queenan
    Johnson and Johnson Pharmaceutical Research and Development, L L C, Raritan, NJ 08869, USA
    Clin Microbiol Rev 20:440-58, table of contents. 2007
    ..This review updates the characteristics, epidemiology, and detection of the carbapenemases found in pathogenic bacteria...
  92. pmc Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents
    T L Pitt
    Laboratory of HealthCare Associated Infection, Specialist and Reference Microbiology Division, Health Protection Agency, 61 Colindale Avenue, London NW9 5HT, UK
    Thorax 58:794-6. 2003
    ..Respiratory infection with Pseudomonas aeruginosa is very common in patients with cystic fibrosis (CF) but antimicrobial resistance rates of CF isolates across the UK are largely unknown...
  93. ncbi The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections
    James A Driscoll
    Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA
    Drugs 67:351-68. 2007
    ..Multidrug-resistant P. aeruginosa may require treatment with less commonly used antibacterials (e.g. colistin), but newer anti-pseudomonal antibacterials are expected to be available in the near future...
  94. pmc Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization
    Rebecca H Sunenshine
    Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Emerg Infect Dis 13:97-103. 2007
    ..5, 95% CI 1.2-5.4 and OR 4.2, 95% CI 1.5-11.6] respectively). Increased hospitalization associated with MDR Acinetobacter infection emphasizes the need for infection control strategies to prevent cross-transmission in healthcare settings...
  95. ncbi Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America
    Alan L Bisno
    Department of Medicine, University of Miami School of Medicine and Veterans Affairs Medical Center, Miami, FL 33125, USA
    Clin Infect Dis 35:113-25. 2002
  96. pmc Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization
    Arunachalam Muthaiyan
    Microbiology Group, Department of Biological Sciences, Illinois State University, Normal, IL 61790 4120, USA
    Antimicrob Agents Chemother 52:980-90. 2008
    ..The results indicate that inhibition of peptidoglycan biosynthesis, either directly or indirectly, and membrane depolarization are parts of the mode of action of daptomycin...
  97. ncbi A global perspective on the use, sales, exposure pathways, occurrence, fate and effects of veterinary antibiotics (VAs) in the environment
    Ajit K Sarmah
    Landcare Research New Zealand Limited, Private Bag 3127, Hamilton, New Zealand
    Chemosphere 65:725-59. 2006
    ..The final section highlights some unresolved questions and presents a way forward on issues requiring urgent attention...
  98. ncbi Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains?
    Kyle J Popovich
    Division of Infectious Disease, Department of Medicine, Rush University Medical Center, and Division of Infectious Disease, Department of Medicine, Stroger Hospital of Cook County, Chicago, Illinois 60612, USA
    Clin Infect Dis 46:787-94. 2008
    ..We describe the epidemiology of hospital-onset community-associated MRSA bloodstream infections using phenotypic and genotypic analysis...
  99. pmc Antimicrobial drug use and resistance in Europe
    Nienke van de Sande-Bruinsma
    National Institute of Public Health and the Environment, Bilthoven, The Netherlands
    Emerg Infect Dis 14:1722-30. 2008
    ..Ecologic studies based on routine surveillance data indicate a relation between use and resistance and support interventions designed to reduce antimicrobial drug consumption at a national level in Europe...
  100. ncbi Inflammatory bowel disease
    Daniel K Podolsky
    Gastrointestinal Unit and the Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, Boston, USA
    N Engl J Med 347:417-29. 2002
  101. pmc Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa
    Mette E Skindersoe
    Biomedical Microbiology, BioSys, Technical University of Denmark, Kgs Lyngby DK 2800, Denmark
    Antimicrob Agents Chemother 52:3648-63. 2008
    ..The data suggest that the underlying mechanism may be mediated by changes in membrane permeability, thereby influencing the flux of N-3-oxo-dodecanoyl-L-homoserine lactone...

Research Grants70

  1. A New Target for Anti-tuberculosis Agents, FAS 1
    John Welch; Fiscal Year: 2003
    ..abstract_text> ..
  2. Therapeutics for Drug-Resistant Bacteria: Myxopyronins
    Richard H Ebright; Fiscal Year: 2013
    ....
  3. Development of a Novel PolC Inhibitor as a Gram-Positive Antibiotic
    THALE CROSS JARVIS; Fiscal Year: 2013
    ..This project represents a compelling opportunity to combat the rising tide of antibiotic-resistant infections, providing a much-needed public health benefit. ..
  4. A common denominator of pathogenesis;a rare opportunity for novel therapeutic de
    DOUGLAS ALAN MITCHELL; Fiscal Year: 2011
    ..A greater understanding of these processes will lay the foundation for developing the next generation of antimicrobial drugs. ..
  5. Novel anti-toxin compounds against Yersinia infections
    Maurizio Pellecchia; Fiscal Year: 2010
    ..Pneumonia, possibly leading to novel broad spectrum antibacterial agents. ..
  6. Protein Structure/Function by NMR, Crystallography and Computational Chemistry
    Eric Oldfield; Fiscal Year: 2012
    ....
  7. In vitro and in vivo efficacy of liposomal ciprofloxacin formulations against Myc
    Igor Gonda; Fiscal Year: 2013
    ..Aradigm already has sufficient safety data in humans and animals to support long-term clinical studies in patients with CFI and DRCFI as well as sufficient cGMP manufacturing in place to support large-scale clinical trials. ..
  8. Impact of the Nasal Microbiome on S. aureus Colonization and Infection
    Mary Bessesen; Fiscal Year: 2013
    ..abstract_text> ..
  9. Design of antituberculosis agents that target siderophore biosynthesis
    Courtney C Aldrich; Fiscal Year: 2013
    ..The proposed research is expected to validate siderophore biosynthesis as new antibacterial target, which may lead to the development of a new class of antitubercular agents. ..
  10. M. tuberculosis genes required for pulmonary survival revealed by TraCS
    MARY HONDALUS; Fiscal Year: 2013
    ..Ultimately this work will contribute to the development of therapeutics which target pathways essential for bacilli survival in the host environment. ..
  11. Analysis of metallo-beta-lactamase sequence constraints at high resolution
    Timothy Palzkill; Fiscal Year: 2013
    ..The detailed knowledge of how active site residue positions contribute to [unreadable]-lactam hydrolysis will facilitate the design of inhibitors that interact with the critically importnt MBL residues. ..
  12. GENETIC ANALYSIS OF PROTEIN EXPORT
    Thomas J Silhavy; Fiscal Year: 2013
    ..Multi-drug resistant Gram- negative bacteria are a growing concern. Insights obtained from this work should facilitate the design of novel antibacterial agents. ..
  13. Development of a Novel Lead Series Against Category A &B Bacterial Pathogens
    Terry L Bowlin; Fiscal Year: 2013
    ..The objective is to develop a new chemical class of broad-spectrum therapeutic agents for use against these threats ..
  14. Discovery of Polymyxin-based Antibacterial Agents Active Against Multi-Drug Resis
    Lawrence H Lash; Fiscal Year: 2013
    ..This will lead to in vivo proof-of-principle for drug action and pharmacokinetic studies for the selection of compounds for future pre-clinical evaluation. ..
  15. Pyruvate Dehydrogenase E1: Structure-Function Studies
    William F Furey; Fiscal Year: 2012
    ....
  16. Novel Antibacterial Drugs Targeting DNA Repair Enzymes
    Gerald R Smith; Fiscal Year: 2010
    ..Drugs against these enzymes should also limit evolution of bacterial resistance and allow more effective treatment of infectious diseases. ..
  17. Characterization of two acyl-CoA carboxylase complexes of Mycobacterium tuberculo
    Hugo Gramajo; Fiscal Year: 2010
    ....
  18. Novel Compounds Targeting Bacterial PBPs
    LUIGI XERRI; Fiscal Year: 2013
    ..Such new products could serve as a critical advance in the search for new treatments for serious multi-resistant bacterial infections in the nosocomial and community settings. ..
  19. The Molecular Control of Cell Death in Staphylococcus aureus
    JEFFREY LEE BOSE; Fiscal Year: 2010
    ..The results generated by these studies will provide a better understanding of the molecular mechanisms controlling bacterial cell death and will lead to novel and more effective therapeutic strategies to combat infections. ..
  20. Characterization of gene cluster for glycophosphoinositides of mycobacteria
    Mary Jackson; Fiscal Year: 2010
    ..tuberculosis that may represent new targets for therapeutic intervention. In addition, the mutants defective in some aspects of GPI synthesis will help define the precise role of these molecules in immunopathogenesis. ..
  21. CONTROL OF VIRUS INDUCED LYSIS
    RYLAND F YOUNG; Fiscal Year: 2013
    ....
  22. Case BMT CTN: Antibacterial Prophylaxis in Post-Engraftment Allogeneic HCT
    Hillard M Lazarus; Fiscal Year: 2013
    ..Our proposed investigations using prophylactic antibacterials have the potential to reduce bacterial infections and GVHD in the post-engraftment phase of allogeneic HCT. ..
  23. Antibacterial Molecular Coatings Pre-Fabricated for Biologic Wound Dressings
    Ankit Agarwal; Fiscal Year: 2012
    ..The new wound dressings will expedite wound closure, reduce use of antibiotics, minimize dressing changes and nurse time, and lower patient pain, medication costs and length of hospital stays. ..
  24. ADHESIN-BASED NANOTHERAPEUTICS IN URINARY TRACT INFECTION
    DAVID ALAN HUNSTAD; Fiscal Year: 2013
    ..We will evaluate the ability of these nanoparticles to prevent and treat UTI. ..
  25. Phase 2 Pharmacodynamic Study of High-dose Levofloxacin in MDR-TB Treatment
    C Robert Horsburgh; Fiscal Year: 2010
    ..The patients will receive their usual treatment, plus the normal dose of levofloxacin or a higher dose. The study will be performed in the Philippines, where multi-drug-resistant TB is common. ..
  26. Antibacterial methionine aminopeptidase inhibitors
    Qi Zhuang Ye; Fiscal Year: 2010
    ..Our multidisciplinary approach with biochemistry, medicinal chemistry, structural biology, and microbiology will be synergistic and will accelerate the drug discovery process. ..
  27. Structure of M. tuberculosis Adenosine Kinase and Design of Antimicrobial Nucle
    Rongbao Li; Fiscal Year: 2010
    ..tuberculosis AK with a lead adenosine analog. These studies will provide molecular basis for development of anti-mycobacterial nucleoside analogs. ..
  28. Novel antibacterial agents resistant to inactivation by polyelectrolytes
    Paul A Janmey; Fiscal Year: 2010
    ..The current proposal will create or retain 4 jobs. ..
  29. Targeting bacterial phosphatases for novel anti-bacterial agents.
    Maurizio Pellecchia; Fiscal Year: 2013
    ....
  30. NMR studies of bacterial needle and tip proteins
    Roberto N De Guzman; Fiscal Year: 2012
    ..The proposed research seeks to elucidate how this needle is assembled by determining the protein-protein interactions of its components. This knowledge will then be used in the design of novel anti-bacterial agents. ..
  31. 2010 Bacterial Cell Surfaces Gordon Research Conference
    Christine Jacobs Wagner; Fiscal Year: 2010
    ..This conference will bring prominent and junior scientists together to present their latest research and to spur collaboration and exchange of ideas and knowledge in a conducive environment. ..
  32. Glycomics of Heparan Sulfate in Bacterial Pathogenesis
    Pyong Woo Park; Fiscal Year: 2010
    ..The results from study could lead to a better understanding on the bacterial infection mechanism and develop heparan-based antibacterial agents. ..
  33. Bacteriolytic phage enzymes as novel antibacterials against Yersinia pestis
    Ian Molineux; Fiscal Year: 2009
    ..pestis infections. These in vivo studies will parallel those involving lysins using the mouse model of plague infection. ..
  34. Intercalated Cells of the Distal Nephron Defend the Urinary System
    Neal Paragas; Fiscal Year: 2013
    ....
  35. Quality Control of Protein Translation
    A Wali Karzai; Fiscal Year: 2012
    ..Ultimately, these insights will have implications for a better understanding of a variety of cellular processes, including control of gene expression, synthesis and degradation of proteins, and the targeted decay defective mRNAs. ..
  36. Synthesis and Evaluation of Antibacterial Anionic Dendritic Amphiphiles
    ERIC LAWRENCE DANE; Fiscal Year: 2013
    ..2) Characterize the supramolecular nanostructures formed by the anionic dendritic amphiphiles. (3) Evaluate the supramolecular nanostructures for antibacterial activity in vitro. ..
  37. Chemical dissection of phospho-signaling that controls the caulobacter cell cycle
    JAMES CHRISTIANSEN ABELLERA BLAIR; Fiscal Year: 2010
    ..By developing a new way to find histidine kinase inhibitors, this work will facilitate systematic development of histidine kinase inhibitors, paving the way to developing a new class of antibiotics. ..
  38. Transcription regulation through RNAP secondary channel
    Dmitry G Vassylyev; Fiscal Year: 2013
    ....
  39. Targeting a novel regulatory RNA with novel antibiotics
    Jennifer V Hines; Fiscal Year: 2010
    ....
  40. Mechanism of proofreading by class I aminoacyl-tRNA synthetases
    John J Perona; Fiscal Year: 2010
    ....
  41. Novel Antibacterial Agents That Target DNA Replication in Mycobacterium tuberculo
    Michael J Pucci; Fiscal Year: 2010
    ..The overall goal of this project is to identify antimicrobial compounds that have the potential to successfully treat both wild-type and MDRTB isolates. ..
  42. COMBATING INFECTION THROUGH ATOMIC-SCALE MODELING OF UNIQUE BACTERIAL SYSTEMS
    JAMES C GUMBART; Fiscal Year: 2013
    ..abstract_text> ..
  43. Genetic determinants of antimicrobial peptide resistance in Gram negative bacteri
    Hyunwoo Lee; Fiscal Year: 2010
    ....
  44. Moving the Field Forward: Evaluation of Antibiotic Prescribing Practices, the Cli
    TIMOTHY CONRAD JENKINS; Fiscal Year: 2013
    ..In summary, the proposed research will provide essential data to move the field of SSTI research forward while facilitating Dr. Jenkins'development into an independently funded investigator. ..
  45. Discovery of inhibitors of the lipopolysaccharide synthesis pathway enzymes LpxA
    Vicki Nienaber; Fiscal Year: 2010
    ..Chemical properties of successful antibiotics have been identified and will be adhered to through the course of this study. ..
  46. Design and analysis of random copolymers with antimicrobial activity
    James C Weisshaar; Fiscal Year: 2013
    ..Random copolymers may find applications in the context of antifungal activity, antiplasmodial activity, and lung-surfactant activity as well. ..
  47. Pan Genomic Discovery of Genes Toxic to Bacteria
    Edward M Rubin; Fiscal Year: 2012
    ..This approach will be used to detect and develop new antimicrobial agents as well as study a new class of RNA molecules that are toxic to bacteria. ..
  48. Single Molecule Studies of Prokaryotic and Eukaryotic Transcription Machineries
    Shimon Weiss; Fiscal Year: 2012
    ..The latter will provide detailed molecular understanding of the causes for transcription related diseases and will provide tools for drug design and screening that will prevent, manage and cure these diseases. ..
  49. Novel Antibacterials Targeting Gram-negative Nonfermenters
    Michelle M Butler; Fiscal Year: 2010
    ....
  50. Metal-titanates as Novel Inhibitors of Cariogenic Biofilms at Tooth-composite Int
    DANIEL CN CHAN; Fiscal Year: 2013
    ..We will study the biofilm collected both in the laboratory and from human subjects with multi-photon laser microscopy. ..
  51. Aminoglycoside Resistance in Bacteria
    Sergei Vakulenko; Fiscal Year: 2013
    ..Design of such novel antibacterial agents will be a breakthrough for treatment of life-threatening infectious diseases. ..
  52. Antibacterial Agents that Restrict the Emergence of Resistance
    ROBERT JOHN KERNS; Fiscal Year: 2013
    ..Application of the ideas to tuberculosis will be significant because on a global basis tuberculosis kills more people than any other infectious disease and because drug-resistant tuberculosis is growing in prevalence. ..
  53. High-Throughput Assay Development for the Discovery of Small Molecule Inhibitors
    CHASE BEISEL; Fiscal Year: 2013
    ....
  54. Novel Inhibitors to DHPS to Probe Catalytic Mechanism &Therapeutic Potential - r
    Stephen W White; Fiscal Year: 2013
    ..aureus and P. jirovecii that have emerged as particularly problematical infectious disease agents in the U.S. in recent years. ..
  55. MECHANISM OF PROTEIN LOCALIZATION IN ESCHERICHIA COLI
    Donald B Oliver; Fiscal Year: 2010
    ....
  56. Creation of a Marine Natural Products Library to Enhance Life Science Research
    Amy E Wright; Fiscal Year: 2010
    ..Such a library will provide access to unique chemical diversity to enhance the US Life Science Research Enterprise. ..
  57. ORGANIC NANOTUBES DESIGN AND BIOLOGICAL APPLICATIONS
    M Ghadiri; Fiscal Year: 2009
    ..abstract_text> ..
  58. PRECLINICAL DEVELOPMENT OF NEW ANTITUBERCULOSIS REGIMEN
    Leonid Heifets; Fiscal Year: 2000
    ..Regimens targeted against dormant tubercle bacilli will include metronidazole and some peptide antibiotics to be developed under Scientific Core A. ..
  59. The Chemistry and Biology of Galactofuranose Residues
    Laura L Kiessling; Fiscal Year: 2013
    ..The goal of this project is to understand key steps in mycobacterial cell wall biosynthesis that are not targeted by any current drugs and find inhibitors from which new types of drugs could be developed. ..
  60. Antibacterial methionine aminopeptidase inhibitors
    Qi Zhuang Ye; Fiscal Year: 2009
    ..coli. The successful completion of this research will help to clarify the in vivo metal for MetAP and providenon- peptidic MetAP inhibitors as leads for effective antibacterial agents to treat infectious diseases. ..
  61. Assess structure and microbial interactions of clay mineral antibacterial agent
    Lynda Williams; Fiscal Year: 2007
    ..abstract_text> ..
  62. Targeted natural product diversification to identify novel antibacterial agents
    ERIN ELIZABETH CARLSON; Fiscal Year: 2011
    ..To achieve this goal, we will develop and apply technologies for the discovery of drug leads from nature's vast reservoir of antibacterial natural products from plants and microorganisms. ..
  63. CONTRIBUTION OF LPS TO EXP ENTEROCOCCAL SEPSIS
    Christopher Papasian; Fiscal Year: 2000
    ....
  64. Development of stable isosteres of dihydrofolate reductase inhibitors as antibact
    Nigel D Priestley; Fiscal Year: 2013
    ..Our goal in this Phase I application is to obtain a clear lead candidate. A Phase II project continuing from this work would then conduct IND-enabling experiments with the clear goal of filing an IND application. ..
  65. 300MHZ NMR SPECTROMETER FOR MEDICINAL CHEMISTRY RESEARCH
    VINCENT DAVISSON; Fiscal Year: 1992
    ....
  66. Modification of Helicobacter pylori Lipid A
    MICHAEL TRENT; Fiscal Year: 2004
    ..pylori and H. heihnannii but also lay the foundation for new molecular insights into the pathogenesis of these unique organisms. ..
  67. Bioanalytical Applications of Capillary Electrophoresis
    FRANK GOMEZ; Fiscal Year: 2005
    ..abstract_text> ..
  68. Syntheses of Amino Acids and Amino Phosphonic Acids
    FRANKLIN DAVIS; Fiscal Year: 2005
    ..Targets include cyclic, unsaturated, and, beta substituted derivatives (beta amino, beta hydroxy, and beta fluoro). ..
  69. MECHANISMS OF TOPOISOMERASE POISONS
    Hiroshi Hiasa; Fiscal Year: 2002
    ..coli extract that could generate DSBs at dead-end topoisomerase complexes. We will identify the protein(s) required for the second step of DSB formation and complete the reconstitution of the DSB process in vitro with purified-proteins. ..
  70. Enzymology of Homoserine Acylation in Methionine Biosynt
    TIMOTHY BORN; Fiscal Year: 2003
    ..All three of these aims directly support the long-term goals of this project. The proposed experiments will be used to train both undergraduate and Master's level students in the area of biochemistry ..